Connect Biopharma Holdings LTD Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Ikarian Capital, LLC and Neil Shahrestani have reported a beneficial ownership of 6.9% in Connect Biopharma Holdings Limited's ordinary shares.
NASDAQ
Wei Zheng has filed a Schedule 13G, disclosing beneficial ownership of 2,520,359 ordinary shares, representing 4.0% of Connect Biopharma Holdings Ltd.
NASDAQ
Wei Zheng has reported beneficial ownership of 3,876,036 ordinary shares, representing 6.2% of Connect Biopharma Holdings Ltd, as of March 31, 2026.
NASDAQ
Biofortune Inc. and Wubin Pan report beneficial ownership of 9.5% and 9.6% respectively of Connect Biopharma Holdings Ltd. ordinary shares as of March 31, 2026.
NASDAQ
SCHEDULE 13G/A: Wei Zheng Boosts Connect Biopharma Stake to 9.9%
Wei Zheng has reported an aggregate beneficial ownership of 9.9% in Connect Biopharma Holdings Ltd, totaling 5,527,528 ordinary shares.